The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | The potential NICE approval of IsaVRd for patients in the UK with transplant-ineligible myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the potential upcoming approval of the isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) quadruplet regimen for patients with transplant-ineligible multiple myeloma (MM) in the UK. Dr Ramasamy highlights that if the combination is approved by the National Institute for Health and Care Excellence (NICE), this would represent a significant change in the treatment of newly diagnosed transplant-ineligible patients, particularly those who are older. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Isatuximab-VRd treatment combination, that has been recently reported in the New England Journal of Medicine and a modification of the same combination reported as the BENEFIT trial in the Nature Medicine publications, are both crucial treatment improvements for newly diagnosed transplant ineligible patients. In the UK, we’re really excited that this treatment combination is going to be looked at by NICE in the next few months...
Isatuximab-VRd treatment combination, that has been recently reported in the New England Journal of Medicine and a modification of the same combination reported as the BENEFIT trial in the Nature Medicine publications, are both crucial treatment improvements for newly diagnosed transplant ineligible patients. In the UK, we’re really excited that this treatment combination is going to be looked at by NICE in the next few months. And this really would be a step change with what we’re currently offering for newly diagnosed transplant ineligible patients.
We currently offer daratumumab in combination with lenalidomide and dexamethasone. And what we have seen with the isatuximab-VRd trials is the proportion of patients who get deep responses is significantly augmented by an additional 20%. This could really mean a critical difference, particularly for the elderly myeloma patients, whose probably key therapy will be just a frontline therapy because their ability to tolerate and be able to receive subsequent lines of therapy is limited. So the ability to give a much better treatment for these patients in the newly diagnosed setting really excites us and we hope that we’re going to be able to have the ability to do so for patients in the UK.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
GSK: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Sanofi: Consultancy, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; Adaptive Biotech: Consultancy, Speakers Bureau; Johnson and Johnson: Consultancy, Speakers Bureau; Menarini Stemline: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Recordati rare Disease: Consultancy, Speakers Bureau.
